chemist72----I'm trying determine exactly how problematic this 510 will be:
"The FDA's warning letter slammed Atossa over its instructions for use, some promotional claims it used for marketing and for not having appropriate clearances for changes made to its nipple aspirate fluid specimen collection process for the MASCT breast pump.
Atossa notes in its recall announcement that MASCT is cleared for fluid sample collection, after which the fluid can be used to determine if cells are normal, precancerous or outright cancer. But the company explains the device hasn't been cleared for breast cancer screening. Sounding contrite, the company also noted that ForeCYTE doesn't have FDA clearance or approval yet "for any indication." The FDA's big worry here is that patients could use both products as a substitute for recommended breast cancer diagnostics or screening and not proceed with the mammograms or biopsies they need.
Appreciate any feedback---tia
ForeCYTE is designed to find precancerous cells and cancer, and help predict the 10-year and lifetime breast cancer risk for women ages 18 to 65. MASCT collects breast fluid noninvasively and then Atossa's lab uses ForeCyte to analyze the results and determine a woman's breast cancer risk in the future."
Read more: Atossa pulls breast cancer Dx after FDA challenges regulatory status - FierceMedicalDevices http://www.fiercemedicaldevices.com/story/atossa-pulls-breast-cancer-dx-after-fda-challenges-regulatory-status/2013-10-07#ixzz2rvNyWNkl
Subscribe at FierceMedicalDevices
"The FDA's warning letter slammed Atossa over its instructions for use, some promotional claims it used for marketing and for not having appropriate clearances for changes made to its nipple aspirate fluid specimen collection process for the MASCT breast pump.
Atossa notes in its recall announcement that MASCT is cleared for fluid sample collection, after which the fluid can be used to determine if cells are normal, precancerous or outright cancer. But the company explains the device hasn't been cleared for breast cancer screening. Sounding contrite, the company also noted that ForeCYTE doesn't have FDA clearance or approval yet "for any indication." The FDA's big worry here is that patients could use both products as a substitute for recommended breast cancer diagnostics or screening and not proceed with the mammograms or biopsies they need.
Appreciate any feedback---tia
ForeCYTE is designed to find precancerous cells and cancer, and help predict the 10-year and lifetime breast cancer risk for women ages 18 to 65. MASCT collects breast fluid noninvasively and then Atossa's lab uses ForeCyte to analyze the results and determine a woman's breast cancer risk in the future."
Read more: Atossa pulls breast cancer Dx after FDA challenges regulatory status - FierceMedicalDevices http://www.fiercemedicaldevices.com/story/atossa-pulls-breast-cancer-dx-after-fda-challenges-regulatory-status/2013-10-07#ixzz2rvNyWNkl
Subscribe at FierceMedicalDevices
Recent ATOS News
- Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial • PR Newswire (US) • 05/27/2026 12:30:00 PM
- Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy • PR Newswire (US) • 05/20/2026 08:45:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:27:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:25:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:25:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:24:42 PM
- Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer • PR Newswire (US) • 05/14/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:45:18 PM
- Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update • PR Newswire (US) • 05/08/2026 12:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 12:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2026 12:00:17 PM
- Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women • PR Newswire (US) • 05/06/2026 12:30:00 PM
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome • PR Newswire (US) • 05/04/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 12:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 11:22:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/30/2026 09:33:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 09:30:46 PM
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/25/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 09:21:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:20:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 08:52:24 PM
- The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology • GlobeNewswire Inc. • 03/19/2026 03:00:00 PM
- Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives • PR Newswire (US) • 03/19/2026 12:00:00 PM
- Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference • PR Newswire (US) • 03/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:22:08 PM
